Decoy Therapeutics explores pan-filovirus program via FDA Animal Rule
Decoy Therapeutics said its next-generation D-MAVs showed potent in-vitro activity against Ebola Zaire and Marburg, and that it is exploring a pan-filovirus program using the FDA Animal Rule pathway and non-dilutive funding, targeting potential FDA Priority Review Voucher eligibility.